PTH and hypoparathyroidism: TransCon technology has also been applied to create sustained release prodrugs of human parathyroid hormone (TransCon PTH) for hypoparathyroidism and of C-type natriuretic peptide (TransCon CNP) for achondroplasia, both of which are currently in late-stage clinical development.